Introduction
============

Cancer of the brain and central nervous system results in an estimated 142,000 mortalities per year, worldwide ([@b1-etm-04-05-0877]). The prognosis is poor for brain cancer patients, with 5-year survival rates of less than one-third ([@b2-etm-04-05-0877]). There are also indications that the incidences of glioma and meningioma have increased over the past few decades ([@b3-etm-04-05-0877]). However, there are few well-established risk factors for glioma and meningioma among adults. Although exposure to ionizing radiation and rare inherited genetic conditions, such as neurofibromatosis ([@b4-etm-04-05-0877]), are known to increase risk, these risk factors only explain a small fraction of reported brain tumors ([@b5-etm-04-05-0877]).

Diabetes mellitus (DM) is a serious and growing health problem worldwide and is associated with severe acute and chronic complications that negatively influence the quality of life and survival of affected individuals ([@b6-etm-04-05-0877]). DM has been recognized as a significant risk factor in several types of cancer, including cancer of the breast, endometrium, pancreas and liver ([@b7-etm-04-05-0877]--[@b10-etm-04-05-0877]). One mechanism to explain the correlation between DM and the risk of cancer is based on the hypothesis that the effect of the insulin and insulin-like growth factors (IGFs) axis triggers intracellular signaling cascades with mitogenic and antiapoptotic effects ([@b11-etm-04-05-0877],[@b12-etm-04-05-0877]). Additionally, studies have found that DM patients have greater oxidative damage to their DNA as measured by the concentration of 8-hydroxy deoxyguanosine in mononuclear cells ([@b13-etm-04-05-0877]).

Due to inconsistent reports on the correlation between diabetes and brain tumor risk ([@b14-etm-04-05-0877]--[@b26-etm-04-05-0877]), the purpose of this study was to summarize all available evidence from published studies and to estimate the risk of brain tumors in patients with diabetes following the meta-analysis of the published studies. Available data were also analyzed according to the various study characteristics.

Materials and methods
=====================

Study identification
--------------------

The electronic databases of PubMed and Embase were searched (up to May 24, 2012) using the following search terms: 'diabetes', 'diabetes mellitus', 'DM', 'brain', 'CNS', 'Central Nervous System', 'cancer', 'neoplasm', 'tumor', 'incidence', 'risk', 'occurrence', 'mortality' and combinations of these terms. All indexed studies were retrieved and we also reviewed the reference lists of the identified publications to discover additional pertinent studies. No language restrictions were imposed. The literature search was carried out independently by two investigators.

Inclusion and exclusion criteria
--------------------------------

The selection criteria were that the study: i) was published as an original article; ii) had DM as the exposure of interest; iii) had brain tumor incidence or mortality as the outcome of interest; iv) provided relative risk (RR), odds ratio (OR), hazard ratio (HR) or standardized incidence/mortality rate (SIR/SMR) with the corresponding 95% confidence intervals (CIs), or presented original data from which to calculate them; and v) at least took age as a confounding factor into consideration in the calculation of RR and corresponding 95% CIs. When there was overlap in the study populations between published papers, only the most recent or complete study was included.

Data extraction
---------------

The following data from each included study were extracted using a standardized data-collection protocol: the first author's name, country of origin, publication year, numbers of cases and subjects, sample size, definition of the study population, ascertainment of exposure and outcome, type of DM, participant characteristics (gender composition), duration of follow-up and variables adjusted for in the analysis. When several risk estimates were presented, we used those adjusted for the largest number of potential confounding factors. Data abstraction was performed independently by two investigators and then cross-checked.

Statistical analysis
--------------------

A meta-analysis of brain tumor risk was conducted. RRs were used as effect estimates. However, some studies reported using OR, HR or SIR estimates. Due to the rare occurrence of brain tumors, we assumed that all these measures would yield similar effect estimates and they were considered equally in the overall effect estimate. Summary RR estimates and the corresponding 95% CIs were calculated for all studies combined and by subgroups using the methods of DerSimonian and Laird with the assumptions of a random-effects model that considered intra- and inter-study variation ([@b27-etm-04-05-0877]). If studies reported RRs for each gender or various types of DM, we calculated a pooled RR and its corresponding 95% CI to determine the overall effect. Statistical heterogeneity between studies was evaluated using Cochran's Q test and the I^2^ statistic ([@b28-etm-04-05-0877]). For the Q statistic, P\<0.10 was considered to indicate statistically significant heterogeneity, and a value of I^2^\>50% was also considered to indicate significant heterogeneity ([@b29-etm-04-05-0877]). Potential sources of heterogeneity were explored by meta-regression analysis. Funnel plots and Begg's test were used to assess the potential publication bias ([@b30-etm-04-05-0877]). Statistical analyses were carried out with STATA version 11.0 (StataCorp, College Station, TX, USA). All tests were two-sided. P\<0.05 was considered to indicate statistically significant differences.

Results
=======

Search results and study characteristics
----------------------------------------

A total of 13 studies, including the entire Danish population, 5,107,506 other participants and over 2,206 cases of brain tumors, were found to match our inclusion criteria. Of these 13 studies, 4 were conducted in the Asia-Pacific region, 2 in the United States and 7 in Europe. Characteristics of the studies included in the meta-analysis are shown in [Table I](#t1-etm-04-05-0877){ref-type="table"}.

Quantitative data synthesis
---------------------------

The combined results based on all studies demonstrated that there was a there was a similar correlation between DM and brain tumor risk (SRR, 1.12; 95% CI, 0.89--1.42; Q, 185.57; P\<0.001, I^2^, 93.5%; [Fig. 1](#f1-etm-04-05-0877){ref-type="fig"}).

We then conducted subgroup meta-analyses by gender, geographical region, types of DM and level of adjustments. A statistically significant positive correlation was detected between DM and brain tumor risk in females (SRR, 1.242; 95% CI, 1.026--1.502) but not in males (SRR, 1.024; 95% CI, 0.938--1.119), and there was clear heterogeneity in the analysis of female subjects (P=0.035; I^2^, 55.8%). Furthermore, positive associations were observed between diabetes and brain tumor risk in the diabetes assessment by self-report and by blood glucose level groups (SRR, 1.136; 95% CI, 1.017--1.268). However, no differences were found in brain tumor risk with diabetes between strata in the geographic region, types of diabetes, the number of cases, population size, duration of follow-up and level of confounding factors ([Table II](#t2-etm-04-05-0877){ref-type="table"}).

Meta-regression analyses were conducted to investigate the sources of heterogeneity between studies according to the above subgroups, however, we did not find a significant source of heterogeneity. Subsequently, we investigated whether the source of heterogeneity was a single study using a meta-regression analysis and found that the study by Hemminki *et al* ([@b21-etm-04-05-0877]) explained 88.91% heterogeneity.

A sensitivity analysis was carried out by omitting one study at a time and calculating the pooled RRs for the remainder of studies. The study by Hemminki *et al* ([@b21-etm-04-05-0877]) appeared to have a strong influence on the meta-analysis estimate of effect. After this study was excluded, we found that the pooled SRR changed slightly (SRR, 1.038; 95% CI, 0.950--1.134). We did not observe notable changes when the other studies were omitted.

In the publication bias test the shape of the funnel plots appeared to be symmetrical for all studies investigating DM and the risk of brain tumors ([Fig. 2](#f2-etm-04-05-0877){ref-type="fig"}). Begg's test did not suggest any evidence of publication bias (P=0.669).

Discussion
==========

In this meta-analysis, we revealed that DM was associated with a 12% increased risk of brain tumors, however, this correlation was not statistically significant. However, a significant positive correlation between diabetes and brain tumor risk was observed in females, but not in males. This result was independent of the geographic region, type of diabetes, number of cases, population size, duration of follow-up and the level of confounding factors.

The null link between a history of diabetes and the risk of brain tumors is particularly notable since one of the hypothesized mechanisms for this association is via insulin resistance with secondary hyperinsulinemia. Hyperinsulinemia has been shown to increase the concentration of bio-available IGF-1 by reducing the concentration of IGF-binding proteins([@b31-etm-04-05-0877]). The insulin and IGF axes are crucial in cell proliferation and apoptosis and thus may affect carcinogenesis([@b31-etm-04-05-0877],[@b32-etm-04-05-0877]). IGFs also exert an important role in the differentiation, proliferation and apoptosis of brain cells in early brain development and this may be a biologically feasible mechanism for an association between brain tumor risk and diabetes([@b33-etm-04-05-0877]). However, it was demonstrated that although high concentrations of IGF-I are positively correlated with the risk of low-grade gliomas and acoustic neuromas, they are not correlated with the risk of high-grade gliomas and meningiomas([@b34-etm-04-05-0877]).

Increased circulating insulin levels have a number of indirect effects, including decreasing the hepatic synthesis and blood levels of sex hormone-binding globulin, leading to increases in bio-available estrogen levels in males and females ([@b12-etm-04-05-0877]). Findings suggest that female sex hormones are protective against glioma ([@b35-etm-04-05-0877]). Since gliomas, including some of the most lethal types of cancer, account for over 80% of brain and central nervous system cancers ([@b36-etm-04-05-0877]), this may be a plausible mechanism to explain the null link between a history of diabetes and the risk of brain tumors when the large proportion of gliomas in brain tumor cases is taken into consideration.

In the subgroup analysis stratified by gender, our results showed that diabetes was associated with a significantly increased risk of brain tumors in females. Increased levels of insulin in blood circulation have been shown to induce an increase in the level of bio-available testosterone in females but not in males ([@b12-etm-04-05-0877]). Furthermore, obese males have lower levels of testosterone ([@b37-etm-04-05-0877]). There is evidence that testosterone stimulates cell growth and local production of IGF-I and IGF-I-R ([@b38-etm-04-05-0877]). This evidence may provide a plausible explanation for the positive correlation of brain tumor risk with diabetes in females, but not in diabetic males.

The strengths of the present study are as follows: i) our meta-analysis was based on 13 studies, the majority of which were prospective studies, thereby minimizing the possibility of recall or selection bias; ii) all included studies evaluated multiple potential confounding factors, some of which were considered to be risk factors for cancer, such as alcohol use, smoking and body mass index; iii) the varied populations of the studies expanded on prior observational studies by permitting additional subgroup evaluation (e.g., by gender, geographic region, type of DM and sources of population).

As with any meta-analysis of observational studies, there are several potential limitations to the results of this meta-analysis. Firstly, significant heterogeneity existed across studies, throwing some doubt on the reliability of the summary RR estimates. Although we found the main source of heterogeneity to be one study, we are unable to account for how this study differed from the others. Secondly, the majority of studies included in this meta-analysis did not distinguish between type 1 and type 2 DM. This non-differential misclassification may distort the magnitude of the association between DM and the risk of brain tumors. Thirdly, the history of DM may also reflect other factors associated with an unhealthy lifestyle, such as smoking, heavy alcohol consumption and obesity. Such unhealthy lifestyles have generally been associated with an increased risk of cancer. However, some authors did not adjust for those risk factors. Fourthly, the status of DM was self-reported in some studies. This may contribute to bias in the diabetes assessments. Additionally, the majority of studies did not consider the role of anti-diabetic drugs on the occurrence and mortality of brain tumors. This role may also contribute to bias. Finally, as in any meta-analysis, it is possible that an observed association is the result of publication bias, since small studies with null results tend not to be published. However, the results obtained from the funnel plot analysis and formal statistical tests did not provide evidence for such bias.

In summary, the results of this meta-analysis suggest a non-significant association between diabetes and the risk of brain tumors. However, compared with non-diabetic patients, diabetic females may have a slightly increased risk of brain tumors, whereas this was not the case in diabetic males. It should be noted that this meta-analysis does not provide firm evidence of any association between DM and brain tumor risk. Future studies are required to determine the role of a history of DM in brain tumor incidence or mortality.

![Forest plots of DM association with risk of brain tumors. Squares are study-specific relative risk. Diamonds are summary relative risks (SRRs). Horizontal lines represent 95% confidence intervals (CIs).](ETM-04-05-0877-g00){#f1-etm-04-05-0877}
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###### 

Characteristics of cohort studies of diabetes and brain tumor incidence and mortality.

  First author (Refs.)                   Source and starting-ending year   Study design   No. of participants           Diabetes assessment                             Outcome ascertainment         Cases   Type of DM      FU (years)   Confounding factors
  -------------------------------------- --------------------------------- -------------- ----------------------------- ----------------------------------------------- ----------------------------- ------- --------------- ------------ ---------------------------
  Adami HO ([@b14-etm-04-05-0877])       Sweden 1965--1983                 Cohort         51,008 (M/F)                  Medical records                                 Cancer registry               66      No assessment   Mean 5.2     1,5
  Wideroff L ([@b15-etm-04-05-0877])     Denmark 1977--1989                Cohort         109,581 (M/F)                 Discharge diagnosis                             Cancer registry               159     No assessment   Mean 5.7     1,2,5,11
  Zendehdel K ([@b16-etm-04-05-0877])    Sweden 1965--1999                 Cohort         29,187 (M/F)                  Discharge diagnosis                             Cancer registry               32      Type 1          Mean 14.4    1,2,5,11
  Coughlin SS ([@b17-etm-04-05-0877])    USA 1982--1998                    Cohort         1,056,243 (M/F)               Self-report                                     Mortality registry            87      No assessment   Mean 14.7    1,4,7,8,9,10, 13,14,15,16
  Jee SH ([@b18-etm-04-05-0877])         Korea 1992--2002                  Cohort         829,770 (M)                   Self-report or blood glucose level              Cancer registry and records   NA      No assessment   Mean 10      1,3,8,9
  Swerdlow AJ ([@b19-etm-04-05-0877])    UK 1972--1993                     Cohort         28,900 (M/F)                  Discharge diagnosis                             Cancer registry               16      Type 1 and 2    Mean 18      1,2,5,17
  Chodick G ([@b20-etm-04-05-0877])      Israel 2000--2010                 Cohort         100,595 (M/F)                 Self-report or blood glucose level              Cancer registry               12      No assessment   Mean 8       1,6,7,19,26
  Hemminki K ([@b21-etm-04-05-0877])     Sweden 1964--2007                 Cohort         125,126 (M/F)                 Medical records                                 Cancer registry               304     Type 2          Median 15    1,2,6,18,20,29
  Shu X ([@b22-etm-04-05-0877])          Sweden 1964--2006                 Cohort         24,052 (M/F)                  Discharge diagnosis                             Cancer registry               20      Type 1          Mean 18.3    2,6,27,28
  Atchison EA ([@b23-etm-04-05-0877])    USA 1969--1996                    Cohort         594,815 (M)                   Discharge diagnosis                             Cancer registry               527     No assessment   Mean 10.5    1,2,4,18,23
  Lam EK ([@b24-etm-04-05-0877])         Asia Pacific region NA            Cohort         367,361 (M/F)                 Self report, diagnosis or blood glucose level   NA                            168     No assessment   Median 4     1
  Carstensen B ([@b25-etm-04-05-0877])   Denmark 1995--2009                Cohort         The Danish population (M/F)   Medical records                                 Cancer registry               418     No assessment   NA           1,2,5,12,21,22
  Lo SF ([@b26-etm-04-05-0877])          Taiwan 1996--2009                 Cohort         1,790,868 (M/F)               Medical records                                 Cancer registry               397     Type 2          Median 3.5   1,2,23,24,25

NA, not available; DM, diabetes mellitus; FU, follow up; M, male; F, female; Confounding factors: 1, age; 2, gender; 3, age2; 4, ethnicity; 5, calender year; 6, region; 7, body mass index; 8, smoking; 9, alcohol consumption; 10, red meat consumption; 11, excluding the first-year of follow-up; 12, excluding the first month-year of follow-up; 13, education; 14, consumption of citrus fruits and juices; 15, consumption of vegetables; 16, physical activity; 17, country-specific person-years at risk; 18, obesity; 19, cardiovascular diseases; 20, socioeconomic status; 21, duration of diabetes/insulin treatment; 22, date of birth; 23, chronic obstructive pulmonary disorder; 23, urbanization; 24, hypertension; 25, hyperlipidemia; 26, Supplemental Educational Services (SES) level; 27, age at first hospitalization; 28, period of diagnosis; 29, time period.

###### 

Subgroup analysis of relative risks for the association of diabetes with brain tumor risk.

                                                                            Heterogeneity             
  ----------------------------------------- ---- -------------------------- --------------- --------- ------
  Total                                     13   1.121 (0.887--1.417)       185.57          \<0.001   93.5
  Gender                                                                                              
    Male                                    8    1.024 (0.938--1.119)       9.82            0.278     18.5
    Female                                  6    **1.242 (1.026--1.502)**   13.58           0.035     55.8
  Geographic region                                                                                   
    Asia Pacific                            4    0.995 (0.879--1.417)       0.87            0.834     0
    Europe                                  7    1.257 (0.888--1.779)       88.87           \<0.001   93.2
    North America                           2    0.922 (0.846--1.005)       0.48            0.487     0
  Types of diabetes                                                                                   
    Type 1                                  3    1.04 (0.803--1.348)        15.21           0.033     54
    Type 2                                  3    1.177 (0.525--2.638)       97.13           \<0.001   97.9
    No assessment                           8    1.061 (0.939--1.198)       15.21           0.033     54
  Diabetes assessment                                                                                 
    Self-report or blood glucose level      6    **1.136 (1.017--1.268)**   4.41            0.492     0
    Medical diagnosis or records            7    1.186 (0.831--1.693)       179.77          \<0.001   96.7
  Population size                                                                                     
    ≥300,000                                6    1.027 (0.909--1.161)       12.92           0.024     61.3
    \<300,000                               7    1.192 (0.79--1.8)          77.94           \<0.001   92.3
  Cases among subjects                                                                                
    ≥150                                    6    1.199 (0.844--1.704)       177.8           \<0.001   97.2
    \<150                                   6    1.023 (0.873--1.199)       3.17            0.674     0
  Follow-up time (years)                                                                              
    ≥10                                     7    1.13 (0.733--1.741)        170.96          \<0.001   96.5
    \<10                                    5    1.034 (0.935--1.143)       2.44            0.656     0
  Level of considered confounding factors                                                             
    ≥5                                      6    1.168 (0.809--1.685)       180.17          \<0.001   97.2
    \<5                                     7    1.099 (0.969--1.245)       2.92            0.819     0

RR, relative risk; CI, confidence interval. Bold type indicates that the 95% Ci does not include 1.00.
